Tumor targeted radiopharmaceuticals, Deborah Charych, co-founder of RayzeBio, Inc,
An emerging field of oncology is the delivery of radiopharmaceuticals to tumors. Deborah Charych is the scientific founder of RayzeBio Inc., launched with co-founders Aaron Kantoff and Aron Knickerbocker in Februaruy, 2020 at the start of the pandemic, raising a $45M Series A in May, 2020.
▶︎
The Science Series: ADCs and radiopharmaceuticals
▶︎
IAEA/ESNM Webinar - Basic Principles of Radionuclide Therapy and Common Clinical Applications
▶︎
2026 June Accelerating the Discovery and Development of GLP-1 Based Therapeutics with MID3
▶︎
Engineering Functionally Improved CAR T cells with a Multi-Cytokine Backpack Platform | REBEL System
▶︎
The World's Most Important Machine
▶︎
Exploring the structural basis for kinetic transitions with 5D-SSX
▶︎
What do tech pioneers think about the AI revolution? - The Engineers, BBC World Service
▶︎
CAR T and Bispecific Antibody Therapies in Multiple Myeloma
▶︎
"The Future of Osteoporosis Treatment" by Dr. Marc N. Wein, MD., PHD
▶︎
Doctor reveals undisclosed risks of COVID-19 vaccine
▶︎
산책은 소용 없습니다. 숨차게 뛰어야 하는 과학적인 이유 (서울대 의대 재활의학교실 정세희 교수)
▶︎
MPG Primer: Connecting GWAS and eQTLs through colocalization (2024)
▶︎
Which country has the best education in the world? - The Global Story podcast, BBC World Service
▶︎
Radiopharmaceuticals: Established Evidence and Process of Implementation of a Theranostics Program
▶︎
Physics Hours ft. Dr Claudiu Gradinaru
▶︎
Will AI destroy the economy?
▶︎
Multiple Myeloma 101 for 2025: Diagnosis, Prognosis, and Risk
▶︎
Bioinformatic Approach for Drug Discovery FKUH
▶︎
Medical breakthroughs and health stories | 60 Minutes Marathon
▶︎